Long-term efficacy and safety of dazukibart in dermatomyositis in adults

Dazukibart, a new anti-interferon beta monoclonal antibody, has been shown to be effective and safe in adults with moderate to severe dermatomyositis in a 24-week randomised phase II trial (NCT03181893). Its 52-week open-label extension with a 16-week follow-up (NCT05192200) enabled its long-term evaluation.

  • Skin lesions improved by week 76, particularly in patients with predominantly cutaneous disease, with a median reduction of 24 points in the CDASI-A (Cutaneous Dermatomyositis Disease Area and Severity Index-Activity) score compared with baseline.
  • In the predominantly muscular cohort, a major improvement in muscle function (defined as a Total Improvement Score or TIS ≥ 60 points) was observed in 60 per cent of participants at week 76 and was maintained in one-third of them at week 92.
  • Dazukibart was well tolerated, with mainly mild or moderate adverse effects.

The rapid and sustained response observed highlights the therapeutic potential of targeted inhibition of the IFN-β pathway. A phase III trial is currently recruiting participants, notably in France (NCT05895786), to confirm these results.